REVIEW: Cancer Research UK’s first Risk Based Monitoring (RBM) workshop

February 1st saw Cancer Research UK’s first Risk Based Monitoring (RBM) workshop for members of the ECMC network in collaboration with the CRUK Combinations Alliance group and the Centre for Drug Development (CRUK CDD).

It was a full day event with participants sharing different approaches to RBM, as well as partaking in group discussions and exercises to share hints/tips, their experiences and concerns around implementing RBM . The workshop was chaired by Zoe Boylan (Combinations Alliance) and Sherraine Hurd (CDD) and included a number of guest speakers from Barts, Oxford and UCL ECMCs as well as RBM expert Andy Lawton representing TransCelerate.

The interactive workshop allowed participants to discuss the different ways to approach and implement RBM. It looked at which criteria should be assessed in both study and site risk assessments, with a focus on Phase I. Andy Lawton challenged the amount of time spent on performing source data verification in comparison to the small amount of data corrections that occurred as a result. He also demonstrated the uses and benefits of RBM on a global scale, with supporting data and implementation tools, all of which had a very positive impact on the workshop participants.

The workshop enabled all the participants to broaden their learning and experience of RBM. It provided the opportunity for networking and allowed members to discuss openly their concerns and generate solutions. With the day having achieved so much, there are now discussions regarding the running of further workshops in this area.

If you would like to provide any feedback on the day or have input for future meetings, please contact:

Zoe Boylan (zoe.boylan@cancer.org.uk)

Sherraine Hurd (sherraine.hurd@cancer.org.uk)